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Introduction
Cataract causes blindness or moderate to severe visual impair-
ment in about 62.5 million people globally1. Each year, at 
least 30 million cataract surgeries are required to prevent 
cataract-related blindness2. Owing to the increasing burden of 
cataract (due to the growing ageing population of the world3 
and reduced visual impairment threshold for surgery4,) the 
number of cataract surgeries performed is likely to increase2,5. 
Phacoemulsification is the most commonly performed cata-
ract surgery in developed countries and is rapidly increasing in 
developing countries like India6.
Corneal endothelium pumps fluid out of the corneal stroma, 
prevents the development of corneal oedema and thus 
maintains corneal transparency7. Normally, about 0.3–0.6% 
of the endothelial cells are lost every year8,9. Corneal endothe-
lial cell loss is likely to increase (in varying amounts) after 
any intraocular surgery10. Following injury, endothelial cells 
increase in size and change from a hexagonal to pleomorphic 
shape9. Persistent corneal oedema can occur if the injury causes 
significant endothelial cell loss (below the critical density), 
necessitating corneal transplantation.
Corneal endothelial decompensation is a common cause of 
post-operative poor vision following cataract surgery with 
a reported incidence of 0.5–2% of cataract surgeries11,12. 
Phacoemulsification, particularly in those with certain 
predisposing factors, results in significant endothelial cell damage 
and loss, with corneal decompensation13 and is one of the 
leading indications for corneal transplant across the globe. Corneal 
decompensation constitutes 28% of all the keratoplasties in 
North America; 20.6% in Europe; 21.1% in Australia; 13.6% in 
the Middle East; 15.5% in Asia, and 18.6% in South America14. 
Hence, with an increase in the number of cataract surgeries, 
a significant increase in the incidence of corneal endothelial 
decompensation is anticipated.
Old age, increased nucleus density and high ultrasound energy 
increase the risk of endothelial cell loss during phacoemulsi-
fication13,15,16. To minimise the corneal endothelial cell loss, 
various modulations in phaco platforms and different phaco-
surgical techniques are introduced. The magnitude of endothe-
lial cell loss is directly related to the amount of ultrasound 
energy used16. Hence, power modulation by various means 
(e.g. microburst techniques) is a provision with most phaco 
machines to reduce the amount of ultrasound energy. Addition-
ally, different phaco techniques that decrease the amount of 
ultrasound energy used are employed17–21.
Despite advancement in the phacoemulsification technique, 
corneal endothelial damage continues to be a key concern. 
The proportion of endothelial cell loss that is accounted for 
by the choice of phaco tip position is uncertain. It is speculated 
that the phaco tip, considered to be the source of heat, when 
kept away from the corneal endothelium with the bevel-up 
technique might result in minimal cell loss22. However, in this 
position, the cavitational energy is directed towards the endothe-
lium, which may have a negative impact. It is also possible 
that the bevel-down technique is more cornea-protective, 
with better contact between the phaco tip and the nucleus, 
making power delivery and aspiration more effective23,24.
Previously published studies investigating the impact of 
phaco tip position on the endothelium have reported contra-
dictory results22,25,26. Moreover, these studies were underpow-
ered to detect a significant difference due to small sample sizes 
(n= 25 to 30 in each group). In an artificial eye model study, 
Frohn et al. reported that there was no significant differ-
ence (n=30 experiments, p= 0.7869) in the amount of ultra-
sound waves reaching the cornea in bevel-up and bevel-down 
positions27. However, an artificially controlled environment 
study might not mirror natural eye conditions.
Joshi et al. compared different phaco parameters of 
‘phacoemulsification with a 0-degree phaco tip’ and ‘30-degree 
phaco tip with combination of bevel-up and bevel-down phacoe-
mulsification’, and found no significant difference in both 
groups. However, they did not compare the effect of these 
manoeuvres on corneal endothelial cell loss. Hence, there is no 
consensus regarding the most cornea friendly phaco tip position 
during phacoemulsification28.
The authors were previously conducting a clinical trial explor-
ing the effect of phaco tip position on central corneal thick-
ness (CCT) during phacoemulsification29. CCT was the primary 
outcome as no specular microscope was available. CCT is not 
a definitive measure of corneal endothelial cell loss, as it is 
affected by other factors such as glucose and HbA1c levels. 
CCT is also known to display diurnal variation; being thickest 
in the morning and gradually thinning as the day progresses30–33.
To answer this long-standing clinical question, we propose 
a randomised clinical trial with a robust study design using 
direct chop phacoemulsification technique and specular micro-
scopy, which can non-invasively analyse the morphology of 
endothelial cells.
Objective
To compare the effect of phaco tip position (bevel-up 
vs. bevel-down) on corneal endothelial cell count during 
phacoemulsification.
Trial design and registration
Randomised, multicentre, parallel-group, triple-masked (par-
ticipant, outcome assessor, and statistician) trial with 1:1 
allocation ratio. The trial is prospectively registered in the 
Clinical Trial Registry of India (CTRI/2019/02/017464; reg-
istered on 05/02/2019) with all items from the World Health 
Organization Trial Registration Data Set. This is trial proto-




The study protocol was approved by the ethics committees 
of Yenepoya (Deemed to be) University, Mangalore, India 
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[YEC-1/217/2019] and Manipal Academy of Higher Educa-
tion, Manipal, India [MAHE/ EC/05-19/06]. Any modifications 
in the trial protocol would require ethics committee approval 
and the same shall be communicated to Data Monitoring 
Committee and Clinical Trial Registry of India. The study will 
comply with the Declaration of Helsinki guidelines, local laws, 
and the International Council for Harmonisation - Good Clini-
cal Practice (ICH-GCP) guidelines. After obtaining written 
informed consent from all study participants, the investigators 
will replace participant identifiers with unique research codes. 
Investigators will restrict access to research data by keep-
ing the completed case report forms in a locked room and by 
using password-protected electronic files. All the research 
participants are insured, and any trial-related complica-
tions will be compensated for. Participants will be reimbursed 
for their travel expenses for follow-up visits.
Study settings
1. Department of Ophthalmology, Yenepoya Medical 
College Hospital, Yenepoya (Deemed to be) University, 
Mangalore, India.
2. Netrajyothi Charitable Trust Hospital, Udupi, India
Study period
September 2018 to September 2023.
Inclusion criteria
Patients aged >18 years with immature cataract attending the 
two study centres in Karnataka, India.
Exclusion criteria
History of significant ocular trauma, previous intraocular sur-
gery, shallow anterior chamber (<2.5 mm), endothelial cell count 
<1500 cells/mm2, pseudoexfoliation syndrome, previous/cur-
rent intraocular inflammation (cells/flare/pigment over an 
anterior capsule or endothelium/posterior synechiae), preop-
erative fully dilated pupil <5 mm, and/or corneal endothelial dys-
trophy (presence of corneal guttae noted on slit lamp examination 
or specular microscope), and patients on oral tamsulosin or 
doxazosin. Cases with complications (posterior capsular rent, 
vitreous loss, zonular dialysis, nucleus drop, suprachoroi-
dal haemorrhage, Descemet’s membrane stripping intraopera-
tively, and postoperative endophthalmitis) will also be excluded 
from the analysis, but the rates of any post-randomisation 
exclusion events will be recorded and reported for per 
protocol analysis. Intention-to-treat analysis will also be done 
without any post-randomisation exclusions. However, complica-
tions that occur before the intervention, leading to conversion 
to manual small incision cataract surgery, will be excluded 
from the analysis.
Randomisation and masking
SK/CAG will approach potentially eligible participants attend-
ing the outpatient departments of the study hospitals. A research 
assistant at the study site will provide detailed information about 
the trial and obtain written informed consent. SK/ CAG will 
enrol the consenting participants after screening for exclusion 
criteria. SS will generate a random number sequence using 
a computer, which will be stored in secured envelopes. Cen-
tral randomisation with stratified blocks of variable size will be 
used. Stratification will be done according to the Lens Opaci-
ties Classification System (LOCS) III grading of the cataract into 
two strata (Strata 1: Grade 1, 2 and Strata 2: Grade 3, 4)34. 
On the day of surgery, SK/CAG will contact the central 
randomisation unit and SS will allocate the participants into either 
of the two groups, i.e., bevel-up or bevel-down (Figure 1). SS 
will not be in direct contact with the participants. The trial par-
ticipant, outcome assessor, and statistician will be masked. The 
participant will not be aware of the group to which they were 
randomised and will not be able to differentiate the interven-
tions. The outcome will be assessed by a trained research 
assistant who is unaware of the intervention. An independ-
ent statistician, who is unaware of the random allocation, will 
analyse the data.
Interventions
Figure 2 shows the steps of the surgery. All surgeries will 
be performed under the peribulbar block. The bevel of the 
phaco tip will be held facing up during nucleus management 
in patients randomised to the “bevel-up group” and down in 
the “bevel-down group”. Balanced salt solution (BSS; Inta-
sol, Intas pharma) with 1:1000 adrenaline (0.5 ml in 500 ml of 
BSS) (Epitrate, Sunways) will be used. Intracameral lignocaine, 
phenylephrine, or pilocarpine will not be used.
All surgeries will be performed by a single ophthalmic surgeon 
at each study site (SK and CAG). To familiarise surgeons with 
the techniques, each surgeon will perform at least 25 surger-
ies using each technique before the start of the trial. No strate-
gies to improve adherence to intervention is required as it is 
a one-time procedure.
Phaco platform and parameters
We will use the Sovereign compact phacoemulsification sys-
tem with WhiteStar technology and Ellips (Abbott Medical 
Optics, Abbott Laboratories, Abbott Park, Illinois, USA) for all 
the surgeries. Following are the parameters for the direct chop: 
maximum aspiration flow rate: 32 cc/min; maximum vacuum: 
300 to 410 mm Hg; threshold vacuum: 170 mm Hg; and maxi-
mum power: 40 linear long pulse 8/12 (40%) with Whitestar on 
and occluded: 40 linear short pulse 6/12 (33%) with Whit-
estar on. A 19-gauge, 30-degree phaco tip will be used for 
all surgeries.
Preoperative evaluation
Preoperative evaluation includes uncorrected and corrected 
distance visual acuity (UDVA and CDVA), slit-lamp examination, 
applanation tonometry, an examination of retina with a 
non-contact 78 dioptre lens, and indirect ophthalmoscopy. 
Maximum pupillary dilatation will be noted 20 minutes after 
instillation of tropicamide with phenylephrine eye drops. 
The axial length (AL) and anterior chamber depth will be 
measured using an ultrasonic A-scan (Echorule Pro, Biomedix 
Optotechnik & Devices, Bangalore, India) or optical biometer 
(IOL Master 500, Carl Zeiss). CCT will be measured using an 
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Figure 1. Proposed flow of participants in this trial.
ultrasound pachymeter (Pacscan 300P, Ver 3 Rev U, Sonomed 
Escalon, Lake Success, NY) with an SD ≤0.09, with the 
patient fixating on a distant target. Endothelial cell density 
will be measured using specular microscope SP-1P (Topcon 
Europe Medical BV, Netherlands). Based on the nucleus 
colour, we will clinically estimate the hardness and grade 
according to LOCS III34.
Intraoperative evaluation
We will note the mean phaco power (%), ultrasound time 
(UST), effective phaco time (EPT) (seconds) and the amount of 
irrigating fluid used.
Postoperative treatment
A combination of topical moxifloxacin and dexamethasone 
eye drops, one drop six times a day for the first week and 
gradually tapered over one month, will be administered.
Postoperative evaluation
The following examinations will be done on day 1, day 15 
and at the end of one month: UDVA, CDVA, slit lamp biomi-
croscopy, applanation tonometry, fundoscopy and CCT meas-
urement. The endothelial count will be assessed at the end of 
one month. The coefficient of variation of cell size and per-
centage of hexagonal cells will also be measured. Automatic 
focusing and digital image capture will be used. In the case of 
a blurred and noisy image, the cells will be identified manu-
ally. The approximate centre of the cell will be marked using 
a stylus pen on the captured specular digital image. The 
guidelines for the use of the specular microscope in clinical 
trials as proposed by McCarey et al. will be followed35. Endothe-
lial cell evaluation will be done through the same specular 
microscope throughout the study period at each site. Regu-
lar follow-up visits of the patients will be encouraged through 
telephonic reminders.
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Figure 2. Surgical procedure.
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Outcome measures
Primary outcome: Endothelial cell count at one month 
postoperatively.
Secondary outcome: CCT on days 1, 15, and 30. Intraoperative 
complications will also be noted.
Sample size calculation
Based on a pooled standard deviation of 441.7, this study would 
require a sample size of 215 for each group to achieve a power 
of 90% and a level of significance of 5% (two-sided), for detect-
ing a true difference of 138 cells/mm2 (2516 - 2378) in the 
means between the study groups26,36. Expecting 10% attrition 
in this trial, we would recruit 240 eligible participants in each 
group (total 480).
Data collection and statistical analysis
Research assistants will collect all the relevant data on a case 
report form (CRF). Research assistants at each study site will 
independently enter the data from CRF into a password pro-
tected server. SK will regularly perform source data verification. 
We will follow double data entry method to identify data entry 
errors. In case of any discrepancy, the data query would be sent 
to the research assistant at the trial site to re-check the source 
data and inform the changes, if any. Any changes made in 
the CRF will be signed and dated to have an audit track.
A blind review of the data will be performed. The analysis will 
follow the intention-to-treat principle. ‘Per protocol’ analy-
sis will also be performed excluding patients who experience 
intraoperative and postoperative complications, as the compli-
cations themselves can have a direct impact on the endothe-
lial count. Descriptive statistics will be used to express the 
results. We will compare the mean endothelial cell counts 
between the study groups by bi-variate analysis. To assess 
the CCT difference between the study groups, repeated 
measures analysis of variance will be used. Statistical 
Package for Social Sciences (SPSS) version 16.0 (SPSS Inc. 
Chicago, USA) will be used.
Data monitoring
A data monitoring committee (DMC) with independent mem-
bers is constituted (see Extended data)37. Based on their find-
ings, the DMC will recommend continuation, modification or 
discontinuation, of the trial, with reports to the ethics 
committees.
Investigators will report any serious adverse events to the DMC 
and ethics committee within 24 hours. We will also enlist all 
the adverse events and report using descriptive statistics. We 
will compare the adverse events between the study groups.
Dissemination
The authors will present the results of the trial in conferences 
and publish them in relevant journals. All the de-identified 
data will be uploaded in an online repository at the end of the 
trial.
Study status
The trial is in the recruitment phase.
Discussion
Corneal endothelial cells are precious as they do not regener-
ate, and they only decrease with age. Although endothelial dam-
age of varying degrees is known to occur in all intraocular 
procedures, techniques that minimise the endothelial dam-
age should be favoured. Hence, ophthalmologists are con-
tinually striving to find a more cornea friendly technique of 
cataract surgery. Endothelial cell loss is of utmost importance 
in corneas predisposed to bullous keratopathy (such as those 
with Fuchs endothelial dystrophy) or in eyes likely to have 
more serious endothelial cell damage (e.g., those with a hard 
nucleus, old age, small pupil, and shallow anterior chamber)13,16,38.
The quantum of corneal endothelial loss during phacoemul-
sification seems to be mainly determined by the heat gener-
ated at the phaco tip, cavitation energy, and the amount of 
ultrasound used22–24. The phaco tip position is likely to deter-
mine the impact of these factors on the corneal endothelium. 
Hence, it would be worthwhile exploring the phaco tip posi-
tion (bevel-up or bevel-down) during phacoemulsification 
resulting in minimum corneal endothelial cell loss.
In a trial of 60 patients by Faramarzi et al., the mean (SD) cor-
neal endothelial cell loss was significantly lower (p=0.017) 
in the bevel-up group (156 ± 150) when compared to the 
bevel-down group (332 ± 363). On the contrary, Raskin at el. 
(n=25 in each group) reported that postoperative mean (SD) 
endothelial cell count was significantly more (p=0.02) in 
the bevel-down (2252 ± 310) when compared to bevel-up 
group (2393 ± 321). Based on the sample size and actual 
observed difference between the study groups, the powers 
of the studies were 69% and 36% for Faramarzi et al. and 
Raskin et al., respectively39. Hence, neither of these stud-
ies had enough patients to detect whether a significant dif-
ference truly exists between the study groups. Moreover, 
potential confounders such as cataract grade and masking 
were not explicitly addressed during randomisation or analysis.
A clinical trial can give rise to erroneous results through the 
introduction of bias/systematic errors, confounding (which 
can be restricted by randomisation) and random error (which 
can be minimised by using a large sample size)40. Keeping in 
view the limitations of the previous trials22,25,26, we have adopted 
a robust design (stratified randomisation based on the cataract 
grade and triple-masking) with adequate sample size to detect 
the expected difference in the endothelial cell loss between 
the two groups. Additionally, this trial utilises specular micro-
scopy, which is a fairly objective and non-invasive method 
of measuring the corneal endothelial cell count and morphology41.
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Conclusion
The proposed trial results will guide ophthalmic surgeons in 
choosing the most cornea friendly phaco tip position during 
phacoemulsification and subsequently minimise the incidence 
of iatrogenic bullous keratopathy.
Data availability
Underlying data
No underlying data are associated with this article.
Extended data
Open Science Framework: Does the phaco-TIp position during 
clear corneal Phacoemulsification Surgery adversely affect 
corneal endothelium? TIPS study protocol for a randomised, 
triple-masked, parallel-group trial of bevel-up versus bevel-down 
phacoemulsification. https://doi.org/10.17605/OSF.IO/5YS6W37
This project contains the following extended data:
• DMC charter.docx (Data Monitoring Committee charter)
• Informed consent form.docx (informed consent form in 
English)
• Netra jothi kannada consent 27.5.2019.pdf (informed 
consent form in Kannada)
• Malayalum consent 27.5.2019.pdf (informed consent 
form in Malayalum)
Reporting guidelines
Open Science Framework: SPIRIT and TIDieR checklists 
for “Does the phaco-TIp position during clear corneal 
Phacoemulsification Surgery adversely affect corneal endothe-
lium? TIPS study protocol for a randomised, triple-masked, paral-
lel-group trial of bevel-up versus bevel-down phacoemulsification” 
https://doi.org/10.17605/OSF.IO/5YS6W37
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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